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Condensed abstract: Use of advanced imaging at the time of diagnosis of stage 0-IIA breast 
cancer decreased between 2008 and 2015 in a large statewide collaborative, and remained stable 
for stage IIB disease. This decrease in testing over time resulted in a cost savings, especially for 
patients with stage I disease. 
 
Keywords: breast cancer; CT scan; PET scan; bone scan; cost analysis; healthcare quality 
assessment; diagnostic imaging  
  
Page 2 of 35Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
3 
 
Abstract 
Background: Although national guidelines do not recommend extent of disease imaging for 
patients with newly diagnosed early stage breast cancer because harms outweigh benefits, high 
rates of testing have been documented. The 2012 Choosing Wisely guidelines specifically 
addressed this issue. We examined the change over time in imaging use across a statewide 
collaborative, as well as the reasons for performing imaging and the impact on cost of care. 
Methods: Clinicopathologic data and use of advanced imaging tests (CT, PET, and bone scan) 
were abstracted from the medical records of patients treated at 25 participating sites in the 
Michigan Breast Oncology Quality Initiative (MiBOQI). For patients diagnosed in 2014-15, 
reasons for testing were abstracted from the medical record. 
Results: Of the 34,078 patients diagnosed with stage 0-II breast cancer between 2008 and 2015 
in MiBOQI, 6853 (20.1%) underwent testing with at least one imaging modality in the 90 days 
following diagnosis. There was considerable variability in rates of testing across the 25 sites for 
all stages of disease. From 2008 to 2015, testing decreased over time for patients with stage 0-
IIA disease (all p<0.001) and remained stable for stage IIB disease (p=0.10). This decrease in 
testing over time resulted in a cost savings, especially for patients with stage I disease. 
Conclusions: Use of advanced imaging at the time of diagnosis decreased over time in a large 
statewide collaborative. Additional interventions are warranted to further reduce rates of 
unnecessary imaging in order to improve quality of care for patients with breast cancer. 
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Introduction 
In 2012 the American Society of Clinical Oncology, in conjunction with the American Board of 
Internal Medicine Foundation, released the first of a series of guidelines called Choosing Wisely 
to educate patients and providers about unnecessary procedures.1 One of the so called “Top 5” 
for oncology recommended against the use of advanced imaging with positron emission 
tomography (PET), computed tomography (CT), and radionuclide bone scans in asymptomatic 
patients with newly diagnosed early stage (stage I and II) breast cancer for the purpose of 
detecting metastatic disease. 
The American Society of Clinical Oncology and National Comprehensive Cancer Network 
(NCCN) also both recommend against use of advanced imaging for assessment of patients with 
stage I and II breast cancer if they have no signs or symptoms concerning for metastatic 
disease.2, 3 The rationale behind these recommendations is the low likelihood of the presence of 
metastatic disease in asymptomatic patients with newly diagnosed stage I and II breast cancer.4-7 
In contrast, the NCCN guidelines recommend considering assessment with advanced imaging for 
patients with clinical stage III disease given the higher prevalence of distant metastatic disease in 
these patients. 
In addition to a low potential for benefit from imaging in asymptomatic patients with stage I and 
II breast cancer, there are also considerable harms. Advanced imaging generally requires 
radiation, and cumulative radiation exposure can increase the risk of second malignancies.8 In 
addition, there are often false positive or indeterminate findings on extent of disease evaluation, 
which can cause anxiety, and can lead to the need for invasive biopsies as well as subsequent 
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scans for further evaluation. Other potential harms from imaging are delays in care and increased 
healthcare costs. It is therefore essential to minimize the inappropriate use of advanced imaging 
in this patient population. 
In order to evaluate the variation in use of CT chest, abdomen, and pelvis, PET, and bone scan 
imaging across a single state over time, the Michigan Breast Oncology Quality Initiative 
(MiBOQI) collected data regarding use of advanced imaging in a prospective registry of 25 
participating hospitals. In addition, clinical and non-clinical factors associated with test usage 
were examined. We hypothesized that use of advanced imaging over time has decreased, 
especially since the publication of the Choosing Wisely initiative. 
Methods 
Patient characteristics 
MiBOQI is a Blue Cross Blue Shield of Michigan/Blue Care Network-supported Collaborative 
Quality Initiative comprising 25 hospital systems that abstract comprehensive demographic, 
clinical, and pathologic data on patients with newly diagnosed breast cancer. The members of the 
collaborativ  conduct quality initiative projects, with the goal of improving the care of patients 
with breast cancer across the state of Michigan. Data from patients with stage 0-II breast cancer 
who were diagnosed between 2008 and 2015 and treated at one of the 25 participating MiBOQI 
hospitals were abstracted from the medical record and included in the registry. If a patient was 
treated with primary systemic therapy, the staging was based on clinical stage at presentation. If 
a patient was treated with primary surgery, the staging was based on pathologic stage. 
All patients who present to a participating site within 180 days of diagnosis of a new breast 
cancer and who undergo surgery and/or systemic therapy at that institution are included in the 
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registry, except for patients with male gender, age under 18, and a history of a non-breast 
invasive malignancy diagnosed within 90 days of the breast cancer. If a patient receives 
treatment at two MiBOQI institutions, she is included in the cohort where she received her first 
cancer-directed treatment. 
Diagnosis of breast cancer was based on the date of the initial biopsy that demonstrated cancer. 
Data elements that were abstracted included demographic characteristics, pathologic findings, 
and treatments administered. In addition, dates of all CT, PET, and bone scans performed within 
90 days following diagnosis of breast cancer were abstracted, except for scans that were 
performed for reasons deemed by the data abstractor to be unrelated to the diagnosis and 
evaluation of breast cancer. Scans performed prior to the date of diagnosis were excluded 
because the intent was to capture only those scans done as a result of the breast cancer diagnosis. 
For the cohort of patients diagnosed in 2014-2015, reasons for testing were abstracted from the 
medical record using a pre-defined list of reasons. These reasons were divided into reasons 
considered concordant or non-concordant with guidelines by the authors of the manuscript prior 
to data analysis; the data abstractors were not aware of the classification of each reason. 
Statistical analysis 
All data were analyzed using the statistical package R, version 3.2.3. Overall stage was based on 
a combination of clinical and pathologic stage. For those patients who underwent primary 
surgical resection, pathologic staging (including T and N stage) was used. In contrast, for those 
patients who received treatment with primary systemic therapy, clinical staging was used. 
All patient characteristics were summarized as proportions, and the statistical significance of 
how scan utilization varied with patient characteristics was assessed using univariate and 
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multivariate logistic regression.  Cost savings were computed using scan costs for 2011 listed by 
the Centers for Medicare & Medicaid Services (CMS) (average cost of CT $400, PET $1075, 
and bone scan $290) applied to scan totals per 1000 patients observed in our data in 2010-2011 
and 2015. Statistical significance was defined as a p-value less than 0.05.  
 
Results 
Use of advanced imaging studies 
Of the 34,078 patients diagnosed with stage 0-II breast cancer between 2008-2015 and included 
in the registry, 6853 (20.1%) patients underwent imaging with CT, PET, and/or bone scan for 
any reason within 90 days following diagnosis of breast cancer (Supplemental Figure 1). The 
percentage of those who underwent testing with at least one imaging modality increased with 
increasing stage (Figure 1A). Similarly, the number of scans performed per patient increased 
with increasing stage (Supplemental Figure 2). In particular, almost 25% of patients with stage 
IIB disease underwent at least 3 advanced imaging tests, compared to approximately 12% for 
patients with stage IIA disease and less than 5% for stages 0 and I. Use of each type of imaging 
modality varied. CT scan was used most commonly, with 4953 (14.5%) patients undergoing at 
least one scan within 90 days following diagnosis of breast cancer. At least one bone scan was 
used for the assessment of 3268 (9.6%) patients. PET scans were used least frequently, with 
1602 (4.7%) patients undergoing at least one scan in the 90 days following diagnosis. 
The number of patients who underwent imaging with at least one diagnostic scan decreased over 
time from 2008 to 2015 for stage 0-IIA breast cancer (all p<0.001), and remained stable for stage 
IIB disease (p=0.10) (Figure 1A, Supplemental Table 1).  When specific imaging modalities 
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were examined, the number of patients who underwent imaging with at least one CT scan or at 
least one bone scan decreased for stage 0-IIA breast cancer (p<0.001) (Figures 1B and 1C). For 
PET scans, the number of patients who underwent imaging between 2008 and 2015 decreased 
for stages I and IIA breast cancer (p=0.001) but there was no apparent significant decrease for 
patients with stages 0 and IIB disease (Figure 1D). 
 
Variability across MiBOQI sites 
Across the 25 participating sites, there was considerable variability in the use of imaging tests 
(Figure 2). When examining the number of patients with stage 0 disease who underwent any 
advanced imaging scan during the 90 days following diagnosis, rates of testing varied from 2.5% 
to 43.7%, with a median of 5.5%.  For stages I, IIA, and IIB, the medians were 13.0% (7.6-
55.9%), 30.4% (15.2-66.5%), and 53.1% (27.5-84.9%), respectively. 
The majority of scans performed were CT scans. When examining the number of patients with 
stage 0 disease who underwent any CT scan, rates of testing across the sites varied from 1.3% to 
43.7%, with a median of 4.6% (Supplemental Figure 3A). For stage I, IIA, and IIB, the medians 
were 9.5% (4.6-53.9%), 18.3% (8.3-61.5%), and 32.6% (10.6-69.9%), respectively 
(Supplemental Figures 3B-D).  
Fewer patients underwent testing with bone scans or PET scans. When examining the number of 
patients with stage 0 disease who underwent a bone scan, rates of testing across the sites varied 
from 0% to 19.7%, with a median of 0.7% (Supplemental Figure 3A). For stage I, IIA, and IIB, 
the medians were 3.8% (0-47.0%), 10.7% (2.7-56.0%), and 27.8% (0-64.0%), respectively 
(Supplemental Figures 3B-D). For PET scans, the median for stage 0 was 0.4% (range 0-2.5%), 
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for stage I was 1.8% (0.7-8.2%), for stage IIA was 8.3% (1.0-37.3%), and for stage IIB was 
16.2% (2.8-64.3%) (Supplemental Figure 3). The participating sites with the highest rates of 
testing with CT differed from those with the highest rates of testing with PET. 
 
Associations between patient characteristics and advanced imaging 
Univariate and multivariate analyses were performed to assess associations between patient and 
pathologic characteristics and test ordering (Table 1). On univariate analysis, younger age, black 
race, lower socioeconomic status, higher comorbidity score, and higher clinical stage were 
associated with higher likelihood of advanced imaging. Pathologic characteristics associated 
with advanced imaging on univariate analysis included lack of ER expression, HER2 
overexpression or amplification, higher tumor grade, larger tumor size, and greater number of 
involved lymph nodes. On multivariate analyses, all factors were statistically significant except 
for Charlson comorbidity index, mostly due to its correlation with several other patient factors. 
 
Reasons for testing 
The medical records of patients from 2014-2015 were examined to determine reasons for testing 
(Table 2). Of the 1687 patients who had advanced imaging performed, 55.1% had imaging 
performed for reasons considered to be concordant with guidelines; the remaining 44.9% had 
tests performed for reasons considered non-concordant or not documented in the medical record. 
For patients with stage 0 disease, 4.4% had at least one advanced imaging test performed, of 
which 81% were considered to be concordant. Of those patients who underwent imaging, more 
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than half did so to evaluate patient-reported symptoms, for a non-breast cancer-related condition, 
or for follow-up of an abnormal test. Twenty percent of tests were ordered by outside providers 
for unknown reasons, and an additional 19% didn’t have a clearly documented reason. 
For patients with stage I disease, 10.3% had at least one advanced imaging test performed, of 
which 69% were considered to be concordant. Of those who were tested, 23% of patients 
underwent imaging to evaluate patient-reported symptoms, 21% for follow-up of an abnormal 
test, and 4% because of clinicopathologic features that do not clearly indicate the need for 
imaging, such as abnormal-appearing lymph nodes, large tumor size based on imaging, young 
age, and triple negative disease. Nine percent of tests were ordered by outside providers for 
unknown reasons, and an additional 26% didn’t have a clear reason documented in the medical 
record. 
For patients with stage IIA and IIB disease, 33.8% had at least one advanced imaging test 
performed. For those with stage IIA disease, 52% were considered to be concordant, as opposed 
to 47% of with stage IIB disease. Of those patients who were tested, fewer underwent imaging 
because of patient-reported symptoms or follow-up of an abnormal test compared to patients 
with stage I disease. About one-fifth of patients had testing prior to initiation of neoadjuvant 
chemotherapy. Compared to stage I disease, a higher percentage of patients underwent 
evaluation with advanced imaging because of node positive disease that didn’t meet the criteria 
for clinical stage III disease (14-26%). About one-quarter of tests were performed for reasons not 
clearly documented in the medical record. 
 
Cost impact of decreased testing over time 
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The cost of advanced imaging tests performed in patients diagnosed in 2010-11, prior to the 
publication of the Choosing Wisely recommendations, were compared to the cost of those 
performed in patients diagnosed in 2015. As shown in Table 3, using the average cost for the 
scans based on the CMS fee schedule from 2011 there was a 33% decrease over time in the total 
cost of scans for patients with stage 0-II breast cancer. When divided by stage, there was a trend 
towards a greater savings for those with stage I disease (36%) compared to stage 0 or II (16% 
and 23%, respectively).  Similar trends were identified when each individual imaging modality 
was examined. 
 
Discussion 
In this large statewide registry, use of advanced imaging within 90 days of diagnosis of stage 0-
IIA breast cancer decreased between 2008 and 2014. As expected, higher rates of imaging were 
seen in patients at higher risk of disease recurrence. There was considerable variability in use of 
imaging across the 25 participating hospital systems, which varied by both disease stage and 
imaging modality. Symptoms, abnormalities identified on other testing, or other disease 
conditions were identified as the reasons for testing for about half of patients with stage 0 or I 
disease. In contrast, factors associated with more aggressive disease were more commonly cited 
as reasons for testing in those with stage II disease. These findings support and extend those 
previously reported in the literature.9-13 
The Choosing Wisely recommendations were developed to reduce the use of advanced imaging 
in asymptomatic patients with newly diagnosed stage 0-II breast cancer because of the minimal 
benefits and potential harms of testing. The likelihood of having metastatic disease in this setting 
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has been demonstrated to be less than 2% in multiple studies.14, 15 Harms from performing 
unnecessary imaging can include the cost of testing to patients and society, radiation exposure 
from the imaging tests, and anxiety related to testing. 
One additional harm that can arise is the potential need to expose patients to additional radiation 
and/or invasive procedures in order to evaluate abnormal findings.8 However, in the MiBOQI 
registry we did not collect downstream effects of imaging, including frequency of abnormal scan 
results or use of additional imaging or biopsies. Both of these can increase risk to patients as well 
as increase the cost of care. As recently reported in a study of patients with stage II and III breast 
cancer, more than 80% of patients had an abnormality noted on advanced imaging, and 43% 
underwent additional evaluation.14 
Use of testing for patients with stage IIB disease remained high throughout the study period. 
Although asymptomatic patients with stage IIB disease were included in the Choosing Wisely 
recommendations, it is unclear whether these patients should be excluded from routine extent of 
disease evaluation. These patients are at increased risk of having metastatic disease compared to 
those with lower stage breast cancer. In addition, many patients with stage IIB disease undergo 
treatment with primary systemic therapy, and therefore their actual extent of disease is unknown 
at the time of imaging, assuming imaging is performed prior to treatment initiation. Routine use 
of imaging in this population may therefore need to be subjected to further study.  
The reduction in testing within the first 90 days after diagnosis that occurred between 2010-11 
and 2015 resulted in substantial cost savings overall based on the Medicare fee schedule, 
especially in patients with stage I breast cancer. Because of limitations in the registry we were 
unable to account for downstream imaging or biopsies that resulted from initial extent of disease 
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evaluation. Therefore, because of this limitation and the use of Medicare reimbursement rates 
rather than private payer rates, the cost savings is likely greater than was identified in this 
analysis. 
Rates of testing decreased at the 25 participating sites across Michigan during the time period 
that the Choosing Wisely recommendations were published. However, it is unknown what led to 
this reduction. One possibility is the Choosing Wisely campaign itself and the associated media 
coverage, although rates of testing in Michigan appeared to start decreasing prior to the 
publication. In addition, others have demonstrated minimal difference in use of testing before 
and after the publication.11 Furthermore, numerous studies have demonstrated a significant lag in 
the uptake of new guidelines or findings by physicians following their initial publication or 
presentation.16 Therefore it is possible that practice patterns changed in Michigan because of 
increased awareness of MiBOQI participating physicians related to regular discussions of the 
topic at MiBOQI’s Tri-Annual meetings, and subsequent dissemination of the information to 
colleagues at tumor board conferences. A formal collaborative quality initiative was launched in 
May 2013 although the topic was discussed at meetings during the year prior to that time. A final 
possibility is the requirement for prior authorization of advanced imaging tests by insurance 
companies, which may have resulted in fewer imaging tests being performed although may not 
have altered the actual ordering of scans by providers. 
In 2014-15, 20-30% of imaging tests ordered for patients with stage 0-II disease did not have a 
clearly documented reason in the medical record. It is possible that almost all of the testing 
performed in these more recent years was guideline-concordant, but it is difficult to tell because 
of incomplete documentation. Using strategies such as multidisciplinary tumor conference case 
reviews and decision making tools incorporated into the electronic health record could 
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potentially help reduce unnecessary test ordering; the latter has been used for prevention of 
venous thromboembolic disease and reducing overuse of antibiotics.17-19   
The variability of testing across participating hospital systems was also notable, and similar to 
what has previously been reported in the literature.9, 13, 20 Those sites with the highest percentage 
of non-concordant testing of patients with stage II disease treated fewer patients compared to 
those with lower rates of testing, although numerous other sites that treated smaller numbers of 
patients also had low rates of testing. The reasons for the variation are unknown but could be 
related to differences in local practice patterns, patient mix across practice sites, lack of a 
multidisciplinary tumor board, concerns about litigation, or financial pressures. 
Overall, these findings represent changes in frequency of imaging at the time of breast cancer 
diagnosis that have occurred across a single state during the time frame that spanned publication 
of the Choosing Wisely guidelines. Our results are based on a large registry of patients treated in 
a variety of practice settings. Although we used a pre-defined list when assessing reasons for 
testing, the data are limited since they were collected retrospectively by data abstractors with 
physician involvement as needed, and not prospectively at the time of ordering. 
In summary, within MiBOQI the rate of imaging within 90 days of diagnosis of stage 0-IIA 
breast cancer decreased significantly between 2008 and 2015, although imaging in stage IIB 
disease remained relatively stable. This decrease likely reduced exposure to multiple harms, 
including radiation exposure, unnecessary invasive procedures, and financial toxicity. Although 
great strides have been made to date, additional interventions are required to reduce the rates of 
unnecessary testing even further, thereby improving the quality of care for patients with breast 
cancer. 
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Figure Legends 
Figure 1. Percentage of patients who had at least one scan performed, by year. Each line 
represents a different disease stage (blue: stage 0, red: stage I, green: stage IIA, purple: stage 
IIB). A) At least one scan of any imaging modality. B) At least one CT scan. C) At least one 
bone scan. D) At least one PET scan. 
Figure 2. Percentage of patients who had at least one scan performed, by participating site. Sites 
are listed on the x axis from 1-25. Bars represent different disease stages (blue: stage 0, red: 
stage I, green: stage IIA, purple: stage IIB). 
 
 
  
Page 19 of 35 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
20 
 
 
Table 1. Patient and pathologic characteristics associated with use of advanced imaging. 
  
Scan 
N=6853 
No Scan 
N=27,225 
Univariate 
P value 
Multivariate  
P value 
Age 
 
<50 1740 (25%) 5188 (75%) <0.001 0.020 
 
 
50-69 3503 (19%) 14660 (81%) 
 
 
70+ 1610 (18%) 7377 (82%) 
Race/ Ethnicity 
  
White 5190 (19%) 22243 (81%) <0.001 <0.001 
Black 1163 (27%) 3190 (73%) 
Other 108 (26%) 308 (74%) 
Hispanic 392 (21%) 1484 (79%) 
Socioeconomic 
status (tertiles) 
High 1866 (17%) 9296 (83%) <0.001 <0.001 
Medium 2326 (21%) 8818 (79%) 
Low 2563 (23%) 8696 (77%) 
Missing 98 (19%) 415 (81%) 
Clinical stage 0 476 (7%) 6528 (93%) <0.001 <0.001 
I 2734 (17%) 13211 (83%) 
II 2906 (40%) 4365 (60%) 
III 99 (77%) 29 (23%) 
IV 7 (88%) 1 (12%) 
Missing 631 (17%) 3091 (83%) 
Path tumor stage pT1 3085 (17%) 14640 (83%) <0.001 <0.001 
pT2 1810 (30%) 4169 (70%) 
pT3 116 (46%) 135 (54%) 
pT4 3 (50%) 3 (50%) 
Other 543 (7%) 7536 (93%) 
Missing 1296 (64%) 742 (36%) 
Nodal involvement 
pN0 3473 (15%) 19416 (85%) <0.001 <0.001 
pN1mi 245 (25%) 747 (75%) 
pN1 1425 (39%) 2191 (61%) 
pN2 5 (100%) 0 (0%) 
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Missing 1705 (26%) 4871 (74%) 
Grade 
1 1213 (17%) 6111 (83%) <0.001 <0.001 
2 2610 (23%) 8927 (77%) 
3 2412 (34%) 4735 (66%) 
Missing 618 (8%) 7452 (92%)   
ER positive 
 
5156 (75%) 23122 (85%) <0.001 <0.001 
HER2 positive 
 
1148 (18%) 2220 (11%) <0.001 <0.001 
Charlson 
Comorbidity Index 
0 5309 (20%) 21661 (80%) 0.001 >0.99 
1 745 (21%) 2733 (79%) 
2 508 (21%) 1862 (79%) 
≥3 291 (23%) 969 (77%) 
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Table 2. Reasons for testing, according to medical record documentation, 2014-15. Percentages 
given are percent of the total number of patients with that stage of disease who had imaging 
performed. 
Reason Stage 0 
N=54 
Stage I 
N=423 
Stage IIA 
N=569 
Stage IIB 
N=641 
Concordant 44 (81%) 291 (69%) 295 (52%) 299 (47%) 
Patient-reported symptom 12 (22%) 96 (23%) 55 (10%) 29 (5%) 
Evaluation of abnormal imaging 
study 
5 (9%) 55 (13%) 32 (6%) 29 (5%) 
Evaluation of abnormal lab test 1 (2%) 33 (8%) 18 (3%) 14 (2%) 
Clinical stage III or IV 0 0 13 (2%) 29 (5%) 
Pathologic stage III (but clinically 
lower stage at diagnosis) 
0 6 (1%) 0 1 (0.2%) 
Neoadjuvant chemotherapy 0 13 (3%) 104 (18%) 149 (23%) 
In anticipation of reconstruction 4 (7%) 14 (3%) 8 (1%) 2 (0.3%) 
Testing required by clinical trial 0 0 1 (0.1%) 1 (0.2%) 
Outside provider 11 (20%) 40 (9%) 46 (8%) 36 (6%) 
Unrelated condition 9 (17%) 27 (6%) 15 (3%) 6 (0.9%) 
Lung cancer screening 2 (4%) 3 (0.7%) 3 (0.5%) 3 (0.5%) 
Uncertain recurrence vs new 
primary 
0 4 (0.9%) 0 0 
     
Non-concordant 10 (19%) 132 (31%) 274 (48%) 342 (53%) 
Recommended by tumor board 0 2 (0.5%) 6 (1%) 1 (0.2%) 
Not documented 10 (19%) 110 (26%) 169 (30%) 134 (21%) 
Factors that do not meet guideline 
criteria for imaging 
    
- Node positive 
disease/abnormal 
appearing lymph nodes 
0 8 (2%) 81 (14%) 166 (26%) 
- ER/PR/HER2 negative  0 2 (0.5%) 6 (1%) 6 (0.9%) 
- Large tumor size  0 3 (0.7%) 6 (1%) 21 (4%) 
- Bilateral disease 0 4 (0.9%) 6 (1%) 4 
- Young age 0 1 (0.2%) 0 5 (0.8%) 
Patient requested 0 2 (0.5%) 0 5 (0.8%) 
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Table 3. Cost savings analysis comparing the cost of advanced imaging scans performed within 
90 days of diagnosis per 1000 patients in 2010-11 and 2015, using estimated costs from the 2011 
Medicare fee schedule. 
 
Imaging 
modality 
Stage 
Total cost 2010-
11 per 1000 
patients 
Total cost 2015 
per 1000 patients 
Percentage 
reduction in cost 
All 
All $202,400 $135,754 33% 
0 $40,133 $33,536 16% 
I $141,543 $90,643 36% 
II $433,007 $333,249 23% 
CT scan 
All $113,494 $75,245 34% 
0 $33,500 $25,051 25% 
I $83,112 $47,741 43% 
II $227,826 $152,981 33% 
Bone 
scan 
All $33,485 $17,473 48% 
0 $3,056 $1,465 52% 
I $25,972 $9,254 64% 
II $70,104 $41,373 41% 
PET scan 
All $55,421 $43,035 22% 
0 $3,577 $5,429 -52% 
I $32,459 $16,929 48% 
II $135,076 $110,164 18% 
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Percentage of patients who had at least one scan performed, by year. Each line represents a different 
disease stage (blue: stage 0, red: stage I, green: stage IIA, purple: stage IIB). A) At least one scan of any 
imaging modality.  
Figure 1A  
190x107mm (300 x 300 DPI)  
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Percentage of patients who had at least one scan performed, by year. Each line represents a different 
disease stage (blue: stage 0, red: stage I, green: stage IIA, purple: stage IIB). B) At least one CT scan.  
Figure 1B  
190x107mm (300 x 300 DPI)  
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Percentage of patients who had at least one scan performed, by year. Each line represents a different 
disease stage (blue: stage 0, red: stage I, green: stage IIA, purple: stage IIB). C) At least one bone scan.  
Figure 1C  
190x107mm (300 x 300 DPI)  
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Percentage of patients who had at least one scan performed, by year. Each line represents a different 
disease stage (blue: stage 0, red: stage I, green: stage IIA, purple: stage IIB). D) At least one PET scan.  
Figure 1D  
190x107mm (300 x 300 DPI)  
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Percentage of patients who had at least one scan performed, by participating site. Sites are listed on the x 
axis from 1-25. Bars represent different disease stages (blue: stage 0, red: stage I, green: stage IIA, 
purple: stage IIB).  
Figure 2  
190x142mm (300 x 300 DPI)  
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Diagram of number of patients diagnosed between 2008-2015 who underwent at least one imaging test.  
Supplemental Figure 1  
338x190mm (96 x 96 DPI)  
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Percentage of patients who had scans performed, by stage. On the x axis it denotes patients who had 1, 2, 
or 3 or more scans performed. Each line represents a different disease stage (blue: stage 0, red: stage I, 
green: stage IIA, purple: stage IIB).  
Supplemental Figure 2  
338x190mm (96 x 96 DPI)  
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Percentage of patients who had at least one scan performed, by participating site. Sites are listed on the x 
axis from 1-25. Bars represent different imaging modalities (blue: CT, red: bone scan, green: PET). A) 
Stage 0.  
Supplemental Figure 3A  
338x190mm (96 x 96 DPI)  
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Percentage of patients who had at least one scan performed, by participating site. Sites are listed on the x 
axis from 1-25. Bars represent different imaging modalities (blue: CT, red: bone scan, green: PET). B) 
Stage I.  
Supplemental Figure 3B  
338x190mm (96 x 96 DPI)  
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Percentage of patients who had at least one scan performed, by participating site. Sites are listed on the x 
axis from 1-25. Bars represent different imaging modalities (blue: CT, red: bone scan, green: PET). C) 
Stage IIA.  
Supplemental Figure 3C  
338x190mm (96 x 96 DPI)  
Page 33 of 35 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Percentage of patients who had at least one scan performed, by participating site. Sites are listed on the x 
axis from 1-25. Bars represent different imaging modalities (blue: CT, red: bone scan, green: PET). D) 
Stage IIB.  
Supplemental Figure 3D  
338x190mm (96 x 96 DPI)  
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2008 and 2015, by stage and type of imaging test. 
 
 
Stage Type of scan 2008 2015 P value 
0 At least one scan 11% 5% <0.001 
CT scan 10% 5% <0.001 
Bone scan 3% 1% <0.001 
PET scan 0.57% 0.51% 0.89 
I At least one scan 22% 11% <0.001 
CT scan 16% 9% <0.001 
Bone scan 12% 3% <0.001 
PET scan 2.3% 1.5% <0.001 
IIA At least one scan 36% 24% <0.001 
CT scan 25% 17% <0.001 
Bone scan 21% 10% <0.001 
PET scan 10% 7% <0.001 
IIB At least one scan 53% 49% 0.10 
CT scan 38% 34% 0.75 
Bone scan 32% 23% 0.002 
PET scan 15% 17% 0.75 
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